



Universiteit
Leiden
The Netherlands

Carcinogenicity of insulin analogues

Braak, S.J. ter

Citation

Braak, S. J. ter. (2015, June 18). *Carcinogenicity of insulin analogues*. Retrieved from <https://hdl.handle.net/1887/33222>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/33222>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/33222> holds various files of this Leiden University dissertation

Author: Braak, Bas ter

Title: Carcinogenicity of insulin analogues

Issue Date: 2015-06-18

Carcinogenicity of insulin analogues

Bas ter Braak

Carcinogenicity of insulin analogues

Bas ter Braak

June 2015

ISBN 978-94-6203-829-5

Coverdesign: Daniël ter Braak

Printing: CPI/Wöhrmann Print Service, Zuthpen

© 2015 Bas ter Braak

All pictures in this thesis have been taken by Bas ter Braak.

No part of this thesis may be reprinted, reproduced or utilized in any form or by any electronic, mechanical or other means, now known or hereafter invented, without written permission of the author.

Carcinogenicity of insulin analogues

Proefschrift

ter verkrijging van
de graad van Doctor aan de Universiteit Leiden
op gezag van de Rector Magnificus, prof. mr. C.J.J.M. Stolker,
volgens besluit van het College voor Promoties
te verdedigen op donderdag 18 juni 2015 klokke 10 uur

door

Sebastiaan Johannes (Bas) ter Braak

geboren op 11 augustus 1987 te Zelhem, Nederland

Promotion committee

Promotor

Prof. Dr. B. van de Water Toxicology, LACDR, Leiden University

Co-promotores

Dr. J.W. van der Laan Centre for Health Protection, RIVM, Bilthoven

Dr. C.L.E. Siezen Medicines Evaluation Board, MEB, Utrecht

Overige leden:

Prof. Dr. A.P. IJzerman Medicinal Chemistry, LACDR, Leiden University

Prof. Dr. B. Silva-Lima iMED-UL, Pharmacological Sciences, University of Lisbon

Prof. Dr. J. Jonkers The Netherlands Cancer institute, Amsterdam

Prof. Dr. J. Kuiper BioPharmaceutics, LACDR, Leiden University

Prof. Dr. P.H. van der Graaf Systems Pharmacology, LACDR, Leiden University

This research was conducted at the Division of Toxicology of the Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands.

Table of contents

Chapter 1	1
Aim and scope of thesis	
Chapter 2	7
Insulin treatment and breast cancer risk; a review of in vitro, animal and human evidence	
Chapter 3	27
Classifying the adverse mitogenic mode of action of insulin analogues using a novel mechanism-based genetically engineered human breast cancer cell panel	
Chapter 4	47
Alternative signaling network activation through different insulin receptor family members caused by pro-mitogenic antidiabetic insulin analogues in human mammary epithelial cells	
Chapter 5	69
Mammary gland tumor promotion by chronic administration of IGF1 and the insulin analogue AspB10 in the p53 ^{R270H/+} WAPCre mouse model	
Chapter 6	91
Tumorigenic insulin analogues promote mammary gland tumor development by increasing glycolysis and promoting biomass production	
Chapter 7	111
Summary and discussion	
 Appendix	
References	121
List of abbreviations	133
Samenvatting	137
Curriculum Vitae	144
List of publications	145

